Patent intelligence · US
US 12383631
Immune antigen specific IL-18 immunocytokines and uses thereof
Immune antigen specific IL-18 immunocytokines and uses thereof
Patent details — US 12383631
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 12, 2025
- Expiration
- Aug 7, 2045
- Applicant
- Bright Peak Therapeutics AG
- Claims
- 20
- CPC classes
- A61K, A61K47/6813, A61K47/6849, A61K47/6851
Quick answer
US 12383631 (Immune antigen specific IL-18 immunocytokines and uses thereof) is held by Bright Peak Therapeutics AG. Status: granted. Granted Aug 12, 2025. Expires Aug 7, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Bright Peak Therapeutics AG
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K47/6813, A61K47/6849, A61K47/6851, A61K47/6863, A61K47/6865
More from Bright Peak Therapeutics AG
Related pharmaceutical patents in our USPTO index.
-
US 12350120
Gum-protecting and teeth-whitening strip and preparation method thereof
granted -
US 12220447
Proteolytic enzyme composition
granted -
US 12215133
GIP and GLP-1 dual receptor agonist, pharmaceutical composition, and use
granted -
US 12173062
Modified TNF-α antibodies and uses thereof
granted -
US 12115136
Fortified CBD oil for treatment of PTSD
granted -
US 12097230
Method and composition for treating post operative conditions
granted -
US 11925686
Materials for phototherapies of ophthalmic diseases
granted
Frequently asked questions
What is US patent 12383631?
US 12383631 (Immune antigen specific IL-18 immunocytokines and uses thereof) is held by Bright Peak Therapeutics AG. Status: granted. Granted Aug 12, 2025. Expires Aug 7, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12383631?
Bright Peak Therapeutics AG is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 57 pharmaceutical patents for this assignee.
When does US 12383631 expire?
Our index shows an expiration date of Aug 7, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.